CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2015年 / 5卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-RW2015-001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [41] Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
    Scott, Susan Combs
    Lee, Sarah S.
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 385 - 394
  • [42] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [43] Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER+ breast cancer.
    Deng, Jing
    Tao, Ran
    Fang, Douglas D.
    Tang, Qiuqiong
    Yin, Yan
    Zhang, Kaixiang
    Li, Yuanbao
    Zhai, Guoqin
    Wang, Qixin
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2021, 81 (13)
  • [44] Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2-Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ditzel, Henrik J.
    CANCERS, 2021, 13 (21)
  • [45] 6-Phosphofructo-2-kinase inhibition to increase the efficacy of ER and CDK4/6 inhibitors against ER plus breast cancer
    Lanceta, Lilibeth
    Lypova, Nadiia
    Chesney, Jasson
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2020, 80 (16)
  • [46] Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer
    Haricharan, Svasti
    Punturi, Nindo
    Singh, Purba
    Holloway, Kimberly R.
    Anurag, Meenakshi
    Schmelz, Jacob
    Schmidt, Cheryl
    Lei, Jonathan T.
    Suman, Vera
    Hunt, Kelly
    Olson, John A., Jr.
    Hoog, Jeremy
    Li, Shunqiang
    Huang, Shixia
    Edwards, Dean P.
    Kavuri, Shyam M.
    Bainbridge, Matthew N.
    Ma, Cynthia X.
    Ellis, Matthew J.
    CANCER RESEARCH, 2018, 78 (04)
  • [47] Axillary Downstaging in ER+/HER2- Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
    Kantor, Olga
    Coopey, Suzanne B.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1265 - 1267
  • [48] Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer
    Elias, Anthony D.
    Staley, Alyse W.
    Fornier, Monica
    Vidal, Gregory A.
    Alami, Vida
    Sams, Sharon
    Spoelstra, Nicole S.
    Goodspeed, Andrew
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Gallagher, Rosa I.
    Wulfkuhle, Julia D.
    Petricoin, Emanuel F.
    Zolman, Kathryn L.
    McSpadden, Tessa
    Jordan, Kimberly R.
    Slansky, Jill E.
    Borges, Virginia F.
    Gao, Dexiang
    Richer, Jennifer K.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [49] Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
    David Groheux
    Elif Hindié
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1571 - 1573
  • [50] Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer
    Dowsett, Mitch
    Kilburn, Lucy
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Pogue-Geile, Katherine
    Liu, Yuan
    Jacobs, Samuel A.
    Finnigan, Melanie
    Puhalla, Shannon
    Dodson, Andrew
    Martins, Vera
    Cheang, Maggie
    Perry, Sophie
    Holcombe, Chris
    Turner, Nick
    Swift, Claire
    Bliss, Judith M.
    Johnston, Stephen
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 163 - 174
12345